Wednesday, April 05, 2006
SansRosa Phase I clinical trial
(via Perry on rosacea support),
Sanrosa, AKA SR-01 (I thought it was SR-101), recently renamed to COL-118, is undergoing a Phase I clinical trial at the Mayo Clinic in Scottsdale, Arizona. Principal investigator is Mark V. Dahl MD, who has published before on rosacea including "Topical Metronidazole Maintains Remissions of Rosacea"
They are looking for patients with red cheeks and the clinical outcome will be reduction of redness. If anyone decides to go, do drop us a line. we are happy to report any comments
anonymously!
Full details here:
http://clinicaltrials.gov/ct/show/NCT00279890?order=2
From Perry on rosacea-support:
"Forgive me if this is old news, but the Mayo Clinic is now recruiting patients (approximately 14 more are needed) for the SR-01 product trials.I just spoke with Ms. Jan Light (her link is provided), and she informed me that these Phase 1 trials require 5 trips to the Scottsdale Arizona compound, in a 28 day period. She stressed that since these are phase 1 trials (safety, safety,safety), the patients would have to remain in the area for the duration of the 28 day study."
Previous post on SansRosa:
http://www.rosacea.co.uk/blog/2006/03/sansrosa-now-aka-col-118.html
Sanrosa, AKA SR-01 (I thought it was SR-101), recently renamed to COL-118, is undergoing a Phase I clinical trial at the Mayo Clinic in Scottsdale, Arizona. Principal investigator is Mark V. Dahl MD, who has published before on rosacea including "Topical Metronidazole Maintains Remissions of Rosacea"
They are looking for patients with red cheeks and the clinical outcome will be reduction of redness. If anyone decides to go, do drop us a line. we are happy to report any comments
anonymously!
Full details here:
http://clinicaltrials.gov/ct/show/NCT00279890?order=2
From Perry on rosacea-support:
"Forgive me if this is old news, but the Mayo Clinic is now recruiting patients (approximately 14 more are needed) for the SR-01 product trials.I just spoke with Ms. Jan Light (her link is provided), and she informed me that these Phase 1 trials require 5 trips to the Scottsdale Arizona compound, in a 28 day period. She stressed that since these are phase 1 trials (safety, safety,safety), the patients would have to remain in the area for the duration of the 28 day study."
Previous post on SansRosa:
http://www.rosacea.co.uk/blog/2006/03/sansrosa-now-aka-col-118.html
